An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BELLUS Health to Participate in the Jefferies Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
BELLUS Health Inc. (NASDAQ:BLU) has announced participation in the Jefferies Healthcare Conference from June 8-10, 2022, in New York City. CEO Roberto Bellini will engage in a fireside chat on June 8 at 11:00 a.m. ET. The company focuses on innovative therapies for refractory chronic cough, with its candidate BLU-5937 completing a Phase 2b trial and a Phase 3 program expected to start in H2 2022. Chronic cough affects around 9 million patients in the U.S., highlighting a significant market opportunity for BELLUS Health's therapeutics.
Positive
None.
Negative
None.
LAVAL, Quebec--(BUSINESS WIRE)--
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY from June 8-10, 2022.
Presentation Details:
Event:Jefferies Healthcare Conference Date/Time: Wednesday, June 8th, 2022 at 11:00 a.m. ET Location: New York, NY
A webcast of the fireside chat may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS Health is planning a Phase 3 program, which is expected to begin in the second half of 2022.
Chronic cough is a cough lasting longer than eight weeks. When the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychological effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Forward-Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “potential,” “possible,” “projects,” “plans,” and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health's control. Such statements include, but are not limited to: the potential of BLU-5937 to successfully treat RCC and other hypersensitization-related disorders and benefit such patients; BELLUS Health’s expectations related to its preclinical studies and clinical trials; the timing and outcome of interactions with regulatory agencies; the potential activity and tolerability profile, selectivity, potency and other characteristics of BLU-5937; and the potential applicability of BLU-5937 and BELLUS Health’s P2X3 platform to treat other disorders. Risk factors that may affect BELLUS Health’s future results include but are not limited to: the benefits and impact on label of its enrichment strategy; estimates and projections regarding the size and opportunity of the addressable RCC market for BLU-5937, the ability to expand and develop its project pipeline; the ability to obtain adequate financing; the ability of BELLUS Health to maintain its rights to intellectual property and obtain adequate protection of future products through such intellectual property; the impact of general economic conditions; general conditions in the pharmaceutical industry; the impact of the ongoing COVID-19 pandemic on BELLUS Health’s operations, plans and prospects, including to the initiation and completion of clinical trials in a timely manner or at all; changes in the regulatory environment in the jurisdictions in which BELLUS Health does business; supply chain impacts; stock market volatility; fluctuations in costs; changes to the competitive environment due to consolidation; achievement of forecasted burn rate; achievement of forecasted preclinical study and clinical trial milestones; reliance on third parties to conduct preclinical studies and clinical trials for BLU-5937 and that actual results may differ from topline results once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of BELLUS Health’s product candidate’s development process and its market size and commercial value are dependent upon a number of factors. Moreover, BELLUS Health’s growth and future prospects are mainly dependent on the successful development, patient tolerability, regulatory approval, commercialization and market acceptance of its product candidate BLU-5937 and other products. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health's public filings with the Canadian securities regulatory authorities, including, but not limited to, its Annual Information Form, and the United States Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 40-F, for further risk factors that might affect BELLUS Health and its business.
What is BELLUS Health's participation in the Jefferies Healthcare Conference?
BELLUS Health will participate in the Jefferies Healthcare Conference from June 8-10, 2022, with CEO Roberto Bellini speaking on June 8 at 11:00 a.m. ET.
What product candidate is BELLUS Health developing?
BELLUS Health is developing BLU-5937, a therapeutic for refractory chronic cough, which has completed a Phase 2b trial.
When is BELLUS Health's Phase 3 program expected to start?
The Phase 3 program for BLU-5937 is expected to begin in the second half of 2022.
How many patients in the U.S. suffer from refractory chronic cough?
Approximately 9 million patients in the United States are estimated to suffer from refractory chronic cough.
Where can I access the webcast of BELLUS Health's fireside chat?
The webcast of BELLUS Health's fireside chat can be accessed on their Investors & Media section of the website after the event.
